Literature DB >> 10150497

The continued need for metered dose inhalers.

G Boyd1.   

Abstract

The metered dose inhaler (MDI) is currently the most widely used device in the treatment of adult asthma. It is the delivery system of choice in general practice throughout the world where both MDIs and powder inhalers are available. Up to 70% of all UK adult asthma prescriptions are for an MDI and worldwide the figures are likely to be higher. The MDI can be used to dispense a variety of medications and is currently the most economical device available. The cost of converting all MDIs to equivalent powder inhalers would be prohibitive. Patients, who have difficulty coordinating the operation of an MDI, can use it with a spacer device. This obviates the need for hand-lung coordination and the requirement for more than minimal inspiratory effort. In acute attacks, there is currently no alternative to an MDI with a spacer device for effective, easily administered, emergency treatment outside the hospital environment. In an emergency, an MDI with a spacer can act more rapidly than a nebulizer because it is quicker to set up and use. The MDI is inexpensive, requires no power source and is easily portable. It is therefore important that the MDI continues to be available.

Entities:  

Mesh:

Year:  1995        PMID: 10150497     DOI: 10.1089/jam.1995.8.suppl_1.s-9

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  6 in total

1.  Correcting Metered-Dose Inhaler Technique vs Switching to Turbohaler in Asthmatic Patients a Study on 'Real-Life' Effectiveness.

Authors:  Li-Cher Loh; Pek Ngor Teh
Journal:  Malays J Med Sci       Date:  2004-01

2.  The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.

Authors:  Andrew C Grant; Richard Walker; Melanie Hamilton; Karl Garrill
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

3.  Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.

Authors:  Stephen Rennard; Charles Fogarty; Colin Reisner; Carlos Fernandez; Tracy Fischer; Michael Golden; Earl St Rose; Patrick Darken; Gregory Tardie; Chadwick Orevillo
Journal:  BMC Pulm Med       Date:  2014-07-16       Impact factor: 3.317

Review 4.  Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD.

Authors:  Anthony D'Urzo; Kenneth R Chapman; James F Donohue; Peter Kardos; M Reza Maleki-Yazdi; David Price
Journal:  Pulm Ther       Date:  2019-03-13

Review 5.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

Review 6.  The Diskus: a review of its position among dry powder inhaler devices.

Authors:  H Chrystyn
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.